Tebentafusp for advanced clear cell sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests if a drug called tebentafusp can help people with advanced clear cell sarcoma that cannot be removed by surgery or has spread. It is for people with a specific immune marker (HLA-A*02:01) whose disease has gotten worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced clear cell sarcoma (tumor marker HMB-45 positive) that cannot be removed or has spread.
- You must have a specific genetic marker called HLA-A*02:01.
- You must be in generally good health, with adequate organ function (kidney, liver, blood counts).
- You must have at least one tumor that can be measured on a scan, and your disease must have gotten worse in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug vebreltinib for people with advanced or spreading clear cell sarcoma. The goal is to see if it can shrink tumors and help patients live longer.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial tests a new drug called tebentafusp for people with uveal melanoma that has spread to other parts of the body and who have not yet received any treatment for the metastatic disease. It requires a specific genetic marker (HLA-A*0201) and focuses on whether the drug can shrink or slow the growth of tumors.
This Phase 3 study compares tebentafusp treatment against the doctor’s choice of standard options in people with previously treated advanced melanoma. It aims to see which approach works better for controlling the cancer and improving outcomes.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
Hear when a new HLA-A*0201 Positive Cells Present trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.